Equities

ReNeuron Group PLC

RENE:LSE

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.38
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-61.43%
  • Beta1.2635
Data delayed at least 20 minutes.
More ▼

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)249.00k
  • Net income in GBP-5.07m
  • Incorporated2005
  • Employees34.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 20 3819 8400Fax+44 14 8353 4864
  • Websitehttps://www.reneuron.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Ovoca Bio PLC0.00-4.32m712.55k5.00712.55k5.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
Fusion Antibodies PLC1.58m-2.84m2.91m50.002.91m50.00
IXICO PLC6.00m-1.87m3.38m89.003.38m89.00
TheraCryf PLC396.00k-3.14m3.63m9.003.63m9.00
ValiRx Plc9.60k-2.04m3.90m8.003.90m8.00
Cizzle Biotechnology Holdings PLC0.00-1.72m7.53m67.007.53m67.00
Destiny Pharma PLC0.00-5.66m8.14m19.008.14m19.00
Genflow Biosciences PLC0.00-1.63m8.39m5.008.39m5.00
ImmuPharma PLC0.00-2.92m8.95m5.008.95m5.00
Data as of --. Currency figures normalised to ReNeuron Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 04 Jun 20213.35m0.00%
Hargreaves Lansdown Asset Management Ltd.as of 01 May 20243.30m0.00%
KW Investment Management Ltd.as of 01 May 20243.08m0.00%
Schroder Investment Management Ltd.as of 12 Mar 20212.84m0.00%
IG Markets Ltd.as of 01 May 20242.32m0.00%
HSBC Bank Plc (Market-Maker)as of 01 May 2024698.00k0.00%
abrdn Investments Ltd.as of 01 May 2024591.00k0.00%
HSBC Global Asset Management (UK) Ltd.as of 01 May 2024581.00k0.00%
Partners Investment Co. LLPas of 11 Feb 2020531.85k0.00%
James Brearley & Sons Ltd.as of 01 May 2024501.00k0.00%
More ▼
Data from 11 Feb 2020 - 01 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.